Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease
PLOS One · 16.04.2026 · 21 (4) · e0346878
DOI: 10.1371/journal.pone.0346878 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 16.04.2026. Verfasst von Mazin Abdelghany und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, United States of America. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Though Bayesian methods are flexible, intuitive, and readily incorporated into clinical decision-making, with particular utility when prior information is available, they remain underutilized in the analysis of clinical trials.
Methods
In PINETREE, a Phase 3 randomized controlled trial (RCT) of remdesivir (RDV) for the treatment of outpatients with COVID-19 at high risk of severe disease, the primary outcome of COVID-19–related hospitalization or all-cause death was reanalyzed using a range of reference and data-driven priors. Posterior probability distributions were used to calculate the probability that the estimated hazard ratio (HR) was below a range of clinically meaningful specified thresholds and to estimate the treatment effect and its 95% credible interval (CrI).
Results
Under a minimally informative prior, the posterior probability of an estimated HR less than 1 for COVID-19–related hospitalization or all-cause death was 1 with a posterior median HR 0.13 and 95% CrI 0.02–0.47, recovering the frequentist estimates. Moreover, estimated posterior probability distributions, posterior median HRs, and 95% CrIs were robust across a range of both reference and data-driven prior choices, indicating the strength of the trial data. Lastly, using priors that incorporate historical RCT data, precision of the estimated posterior median HR and 95% CrI was improved over naïve, frequentist estimates.
Conclusions
In a Bayesian reanalysis of the PINETREE trial, there was a 98.9% or greater probability that treatment with RDV reduced the risk of COVID-19–related hospitalization or all-cause death across all prior probability distributions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, United States of America.
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
- Division of Pulmonary, Critical Care & Sleep Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
ORCID-Profile: Mazin Abdelghany, Yeongjin Gwon
Zitieren
APA
Abdelghany, M., Yu, F., Rennard, S., & Gwon, Y. (2026). Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease. PLOS One, 21(4), e0346878. https://doi.org/10.1371/journal.pone.0346878
Vancouver
Abdelghany M, Yu F, Rennard S, Gwon Y. Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease. PLOS One. 2026;21(4):e0346878. doi:10.1371/journal.pone.0346878
BibTeX
@article{Abdelghany2026,
author = {Abdelghany, Mazin and Yu, Fang and Rennard, Stephen and Gwon, Yeongjin},
title = {Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0346878},
doi = {10.1371/journal.pone.0346878}
}
EUVIMED